Amarin Corporation (AMRN) Scripts May Be Underrepresented By Script Data - Cantor

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) noting that sales for Vascepa may be under represented by scripts. Apparently, an increasing percentage of scripts are coming in as 90-day scripts while 30-day and 90-day scripts are both counted as one.

The analyst stated "Our discussions with investors support our optimistic outlook on the market opportunity for Vascepa, and we continue to think that AMRN is an interesting asset in a consolidating space".

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $22.19 yesterday.

You May Also Be Interested In

• Terreno Realty Corp (TRNO) PT Raised to $77 at Cantor Fitzgerald on Leasing Optimism
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• MiMedx Group (MDXG) Reiterated at Overweight by Cantor Fitzgerald: Wound Care Market Stable